scholarly journals Microbiota, Fiber, and NAFLD: Is There Any Connection?

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3100
Author(s):  
Alejandra Pérez-Montes de Oca ◽  
María Teresa Julián ◽  
Analía Ramos ◽  
Manel Puig-Domingo ◽  
Nuria Alonso
Keyword(s):  
Weight Loss ◽  
Gut Microbiota ◽  
Fatty Liver Disease ◽  
Pathogenic Bacteria ◽  
Metabolic Diseases ◽  
Intestinal Barrier ◽  
Alcoholic Fatty Liver ◽  
Fiber Consumption ◽  
Insoluble Fiber ◽  
Alcoholic Fatty Liver Disease

Gut microbiota can contribute to the development and progression of non-alcoholic fatty liver disease (NAFLD). In fact, some specific changes of gut microbiota are observed in patients in what is called dysbiota. There has been a lot of investigation by using a variety of interventions, including diet, showing the possibility to modify components of gastrointestinal dysbiota towards healthy and multivariate microbiota to restore physiologic status. One of the main focuses has been dietary fiber (DF), in which most of its variants are prebiotics. The highest effective treatment for NAFLD is, so far, weight loss achieved by caloric restriction. DF supplementation with oligofructose facilitates weight loss, enhances the production of beneficial metabolites, decreases some pathogenic bacteria population by increasing Bifidobacteria, and has effects on intestinal barrier permeability. DF use has been associated with improvement in diverse metabolic diseases, including NAFLD, by modifying gut microbiota. Additionally, it has been shown that a higher insoluble fiber consumption (≥7.5 g/day) revealed improvements in 3 different scores of liver fibrosis. Further research is needed, but given the evidence available, it is reasonable to prescribe its consumption in early stages of NAFLD in order to prevent disease progression.

scholarly journals NON-ALCOHOLIC FATTY LIVER DISEASE IN THE CONTEXT OF ALTERED GUT MICROBIOTA

2021 ◽  
Vol 74 (4) ◽  
pp. 1007-1010
Author(s):  
Tetyana V. Koval ◽  
Ivan V. Chopey ◽  
Mykhaylo M. Hechko ◽  
Artur V. Kurakh
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Intestinal Microbiome ◽  
Alcoholic Fatty Liver ◽  
Physiological Processes ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

The aim: To analyze the relationship between non-alcoholic fatty liver disease and changes in the gut microbiota. Materials and methods: The publications of domestic and foreign editions in the databases of the United European Gastroenterology (UEG) Journal, PubMed, MEDLINE, Web of Science were processed and analyzed. Conclusions: In recent years, non-alcoholic fatty liver disease was placed among the important diseases in gastroenterology. During this time, more and more data appear on the link between changes in the human intestinal microbiome and the development of metabolic diseases, including NAFLD. Contemporary research has indeed found evidence of such a relationship. Thus, some strains of microorganisms have been identified in more detail, which directly or indirectly affect the development or course of the above-mentioned disease. For a better understanding of the strategies for the treatment of pathologies, it is necessary to delve into the study of etiological factors, therefore, NAFLC cannot be considered a pathology that has been sufficiently studied. Indeed, recent data indicate that the development and severity of the course of the disease are not always associated with the physiological processes already known to us.

scholarly journals The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease

2022 ◽  
Vol 23 (2) ◽  
pp. 662
Author(s):  
Roberta Forlano ◽  
Benjamin H. Mullish ◽  
Lauren A. Roberts ◽  
Mark R. Thursz ◽  
Pinelopi Manousou
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Intestinal Barrier ◽  
Gut Permeability ◽  
Alcoholic Fatty Liver ◽  
Treatment Pathways ◽  
New Treatment ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease worldwide, mirroring the epidemics of obesity and metabolic syndrome. As there are still no licensed medications for treating the disease, there is an ongoing effort to elucidate the pathophysiology and to discover new treatment pathways. An increasing body of evidence has demonstrated a crosstalk between the gut and the liver, which plays a crucial role in the development and progression of liver disease. Among other intestinal factors, gut permeability represents an interesting factor at the interface of the gut–liver axis. In this narrative review, we summarise the evidence from human studies showing the association between increased gut permeability and NAFLD, as well as with type-2 diabetes and obesity. We also discuss the manipulation of the gut permeability as a potential therapeutical target in patients with NAFLD.

scholarly journals Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Hanyan Luo ◽  
Hongwei Wu ◽  
Lixia Wang ◽  
Shuiming Xiao ◽  
Yaqi Lu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Intestinal Barrier ◽  
Therapeutic Effects ◽  
Alcoholic Fatty Liver ◽  
Hepatoprotective Effects ◽  
Underlying Mechanisms ◽  
Alcoholic Fatty Liver Disease

AbstractCassiae Semen (CS), the seeds of Cassia obtusifolia L. and C. tora L, have a long medicinal history in China, with suggestions for it to relieve constipation and exert hepatoprotective effects. However, the underlying mechanisms are still unclear. In this study, mice with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) were used to study the hepatoprotective effects of CS. The relationship between gut microbiota and hepatoprotective effect mechanisms mediated by CS extracts, the total aglycone extracts of CS, rubrofusarin-6-β-gentiobioside, and aurantio-obtusin were examined. Our data indicate that CS extracts and components confer a protective effect by ameliorating lipid accumulation, intestinal barrier damage, liver damage, and inflammation on HFD-induced liver injury. Meanwhile, fecal microbe transplantation exerted the pharmacological effect of CS on HFD-fed mice; however, the efficacy of CS was inhibited or eliminated by antibiotic-induced dysbiosis. In conclusion, the therapeutic effects of CS on NAFLD were closely related to the gut microbiota, suggesting a role for TCM in treating disease.

scholarly journals Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review

Foods ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 1719
Author(s):  
Valentina Castillo ◽  
Fernanda Figueroa ◽  
Karoll González-Pizarro ◽  
Paz Jopia ◽  
Claudia Ibacache-Quiroga
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Communicable Disease ◽  
Anthropometric Parameters ◽  
Alcoholic Fatty Liver ◽  
Risks Factors ◽  
Alcoholic Fatty Liver Disease ◽  
Non Communicable Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.

Sign in / Sign up

Export Citation Format

Share Document